bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prevalence and risk factors of ischemic monocular vision loss and concurrent brain ischemia
Authors: Smith Cathy E , Kukolja Juraj 
Published: August 2023

Introduction: We performed a retrospective cohort study to identify predictors of concurrent asymptomatic brain ischemia in patients with ischemic monocular vision loss. Patients and methods: An inpatient database research of admissions to the Helios University Hospital Wuppertal, Germany between 01/2016 and 12/2020 was conducted. Inclusion criteria were confirmed diagnosis of transient monocular vision loss (MVL), retinal artery occlusion (RAO), and magnetic resonance imaging (MRI) of the brain within 10 days of MVL. Silent brain ischemia (SBI) was defined as diffusion restrictions with corresponding reduced apparent diffusion coefficient in MRI and an absence of neurological deficits besides those complying with MVL in clinical examination. The prevalence and cardiovascular predictors of SBI were analyzed with logistic regression and an artificial neural network. Results: One hundred fourteen out of 475 patients treated with monocular vision loss were included in this study. The mean age was 67.7 ± 13.6 years. 48.2% were male and 47.4% had RAO. MRI scan of the brain was performed after 3.9 ± 2.3 days and detected SBI in 17%. Age ⩾67 years, cardiac etiology of MVL, and cerebral ischemia in medical history were revealed as predictors of SBI in MRI. Conclusions: Patients older than 66 years, with a suspected cardiac embolism as the cause of RAO and previous cerebral ischemia, are more likely to present SBI in cerebral MRI. Therefore, MR imaging, particularly in these patients, can be useful.
Fracture toughness of hybrid natural fiber/nanoclay reinforced starch biocomposite material
Authors: Olusanya John Olumide , Mohan Turup Pandurangan , Kanny Krishnan 
Published: August 2023

In this paper, fracture toughness of banana fiber reinforced thermoplastic starch (BF_TPS) material was studied. Fiber weight percent (30, 40, and 50 wt.%) to starch polymer was fabricated using hot press at a pressure of 5 MPa of 160°C for 30 min. Experimental result shows that 40 wt.% BF_TPS biocomposite gave optimum tensile strength. Furthermore, nanoclay with varying weight percentage (1–5 wt.%) of dry cornstarch (CS) powder was added to enhance the property of the optimum 40 wt.% BF_TPS biocomposite, hence, forming hybrid clay/BF_TPS biocomposite. Tensile, impact, and fracture mechanics (Mode I fracture test) through Single End Notched Bending (SENB) Test were studied concurrently. Thermal properties and degradations were equally studied through Dynamic Mechanical Analysis (DMA) and Thermogravimetric Analysis (TGA). Results show that tensile strength and impact resistance increased to the maximum of 65% and 15.6%, respectively, at 3 wt.% clay addition. Critical stress intensity factor ( K IC) was approximately higher by 276% when compared to neat BF_TPS material. Strain energy release rates ( G IC) values were minimal. Delamination and catastrophic failures occurred with less fiber crack propagation along the crack initiation notches. In TGA, less weight reduction was observed at 3 wt.% clay/BF_TPS material, while a positive shift occurred in DMA tan delta (Tan δ) T g by 30°C. The micrography of the clay-enhanced biocomposites resulted in better bonding interaction between the polymer and fiber.
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
Authors: Sierra Jorge , Montesinos Pau , Thomas Xavier , Griskevicius Laimonas , Cluzeau Thomas , Caillot Denis , Legrand Ollivier , Minotti Clara , Luppi Mario , Farkas Firas , Bengoudifa Bourras-Rezki , Gilotti Geralyn , Hodzic Sejla , Rambaldi Alessandro , Venditti Adriano 
Published: August 2023

Abstract
The pivotal RATIFY study demonstrated midostaurin (50 mg twice daily) with standard chemotherapy significantly reduced mortality in adult patients (&lt;60 years) with newly diagnosed (ND) FLT3mut acute myeloid leukemia (AML). Considering that AML often present in older patients who show poor response to chemotherapy, this open-label, multicenter phase 3b trial was designed to further assess safety and efficacy of midostaurin plus chemotherapy in induction, consolidation, and maintenance monotherapy in young (≤60 years) and older (&gt;60 years) patients with FLT3mut ND-AML. Compared with RATIFY, this study extended midostaurin treatment from 14 days to 21 days, substituted anthracyclines (idarubicin or daunorubicin), and introduced variation in standard combination chemotherapy dosing (“7+3” or “5+2” in more fragile patients). Total 301 patients (47.2% &gt;60 years and 82.7% with FLT3-ITDmut) of median age 59 years entered induction phase. Overall, 295 patients (98.0%) had at least 1 adverse event (AE), including 254 patients (84.4%) with grade ≥3 AE. The grade ≥3 serious AEs occurred in 134 patients. No difference was seen in AE frequency between age groups, but grade ≥3AE frequency was higher in older patients. Overall, complete remission (CR) rate including incomplete hematologic recovery (CR + CRi) (80.7% [95% confidence interval, 75.74-84.98]) was comparable between age groups (≤60 years [83.5%]; &gt;60 to ≤70 years [82.5%]; in patients &gt;70 years [64.1%]) and the type of anthracycline used in induction. CR + CRi rate was lower in males (76.4%) than females (84.4%). Overall, the safety and efficacy of midostaurin remains consistent with previous findings, regardless of age, sex, or induction regimen. The trial is registered at www.clinicaltrials.gov as #NCT03379727.
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Authors: Olszewski Adam J. , Phillips Tycel J. , Hoffmann Marc S. , Armand Philippe , Kim Tae Min , Yoon Dok Hyun , Mehta Amitkumar , Greil Richard , Westin Jason , Lossos Izidore S. , Munoz Javier L. , Sit Jason , Wei Michael C. , Yang Annie , Chen Vivian , Purev Enkhtsetseg , Yee Donald L. , Jaeger Ulrich 
Published: August 2023

Abstract
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study (NCT03677141), 40 patients (52.5% with international prognostic index ≥3) with previously untreated DLBCL initiated 6 cycles of IV mosunetuzumab with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Mosunetuzumab was administered in cycle 1 as step-up doses to mitigate cytokine release syndrome [CRS], and a dose of 30 mg was given on day 1 of cycles 2-6. Efficacy end points included objective and complete response rates, as determined by the investigator, via positron emission tomography–computed tomography, using Lugano 2014 criteria (87.5% and 85.0%, respectively). At a median follow-up of 32.0 months, the estimated 2-year progression-free survival and event-free survival rates were 65.4% (95% confidence interval [CI], 49.5-81.4) and 60.4% (95% CI, 44.7-76.1), respectively. CRS occurred in 60.0% of patients; all events were grade 1 (45.0%) or grade 2 (15.0%) and occurred primarily in cycle 1. Mosunetuzumab-related grade ≥3 neurologic adverse events (AEs) potentially consistent with immune effector cell–associated neurotoxicity syndrome occurred in 1 patient (2.5%). Grade 5 AEs were reported in 2 patients. Neutropenia occurred in 70.0% of patients, mostly during cycle 1 and was of short duration. These findings demonstrate promising activity and a manageable safety profile for mosunetuzumab-CHOP and warrant further investigation of mosunetuzumab in first-line combination regimens for DLBCL.
Patients with cluster headache show signs of insomnia and sleep related stress: results from an actigraphy and self-assessed sleep study
Authors: Ran Caroline , Jennysdotter Olofsgård Felicia , Steinberg Anna , Sjöstrand Christina , Waldenlind Elisabet , Dahlgren Anna , Belin Andrea Carmine 
Published: August 2023

Abstract
Background
Cluster headache (CH) is a primary headache disorder which is characterized by circadian timing of headache attacks, usually at nighttime, in around two thirds of patients. Patients with CH often report sleep difficulties, though it is unknown whether this is a cause or a consequence of nightly headache attacks.

Objective
In this case-control study we have assessed sleep quality in study participants with CH in cluster bout respectively in remission, compared to a control group of neurologically healthy individuals to investigate the potential connection between sleep and CH.

Methods
Fifty study participants with CH and 42 controls were recruited for sleep assessment. Sleep was recorded using MotionWatch 8 actigraphs (CamNTech) for a period of two weeks. Study participants were instructed to wear the unit during rest and sleep and to fill out a sleep diary daily through the two-weeks period.

Results
Results from actigraphy recordings and sleep diaries suggested that patients with CH spend longer time in bed than controls (CH 8.1 hours vs. Controls 7.7 hours, p=0.03), but do not sleep more than controls (CH 6.7 hours vs. controls 6.5 hours, p=0.3). In addition, CH patients reported increased sleep latency (p=0.003), particularly during, but not restricted to, cluster bouts. Study participants with CH further reported higher levels of stress at bedtime (p=0.01), and they felt less well rested than controls (p=0.001).

Conclusion
Our analysis suggests that sleep is negatively affected in CH both in cluster bout and in remission, manifesting in symptoms consistent with insomnia such as prolonged sleep latency and increased time in bed.
A critical examination of the protection level for primary producers in the first tier of the aquatic risk assessment for plant protection products
Authors: Sabine Duquesne , Stephan Brendel , Linda Hönemann , Marco Konschak , Magali Solé , Joern Wogram , Silvia Pieper 
Published: August 2023

Abstract
Background
The aim of environmental risk assessment (ERA) for pesticides is to protect ecosystems by ensuring that specific protection goals (SPGs) are met. The ERA follows a prospective tiered approach, starting with the most conservative and simple step in risk assessment (RA) (so-called tier 1) using the lowest available appropriate endpoint derived from ecotoxicological tests. In 2015, for the tier 1 RA of aquatic primary producers, the recommendation was changed from using the lowest of the 50% inhibition (EC50) values based on biomass (area under the curve—EbC50), increase in biomass (yield- EyC50) or growth rate (ErC50) to only using the growth rate inhibition endpoint (ErC50) because it is independent of the test design and thus more robust. This study examines the implications of this such on the level of conservatism provided by the tier 1 RA and evaluates whether it ensures a suitable minimum protection level.

Results
Our analysis shows that replacing the lowest endpoint with the growth rate inhibition endpoint while maintaining the assessment factor (AF) of 10 significantly reduces the conservatism in the tier 1 RA. Comparing protection levels achieved with different endpoints reveals that the current assessment is less protective. To maintain the previous level of protection, and since the protection goals have not changed, we recommend to multiply the default AF of 10 by an extra factor of minimum 2.4 in the tier 1 RA based on ErC50. Independently of the endpoint selected in tier 1 RA, several issues in the general RA of pesticides contribute to uncertainties when assessing the protection levels, e.g., lack of appropriate comparison of the higher tier experimental studies (i.e., best achievable approximation of field situation, so-called surrogate reference tier) with field conditions or the regulatory framework's failure to consider realistic conditions in agricultural landscapes with multiple stressors and pesticide mixtures.

Conclusions
We advise to consider adjusting the risk assessment in order to reach at least the previous protection level for aquatic primary producers. Indeed continuing using an endpoint with a higher value and without adjustment of the assessment factor is likely to jeopardize the need of halting biodiversity loss in surface waters.
Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol
Authors: Jamora Roland Dominic G. , Khu Kathleen Joy O. , Sy Marie Charmaine C. , Pascual Juan Silvestre G. , Legaspi Gerardo D. , Aguilar Jose A. 
Published: August 2023

AbstractTranscranial magnetic resonance-guided focused ultrasound (MRgFUS) is a noninvasive method for controlling tremor and has recently been used in patients with X-linked dystonia-parkinsonism (XDP). This study aims to determine the improvement in dystonia and parkinsonism in patients with XDP after MRgFUS pallidothalamic tractotomy. This prospective study will be conducted at the Philippine General Hospital, University of the Philippines Manila. The primary outcome measure is the change in the pre- and post-treatment XDP-Movement Disorder Society of the Philippines Scale scores. In addition, demographic and clinical data will be collected, including the Burke-Fahn-Marsden Dystonia Rating Scale, Part III of the Movement Disorder Society-Unified Parkinson’s disease Rating Scale score, XDP clinical and functional stage, the five-level EuroQol five-dimensional questionnaire, Montreal Cognitive Assessment scores, MRgFUS treatment parameters, and adverse events. Patients will be assessed within 24 hours of treatment, then at 2 weeks, 3 months, 6 months, 9 months, and 12 months post-treatment. This protocol was approved by the University of the Philippines Manila Research Ethics Board (UPMREB 2022-0271-01). Data collection began in January 2023. This protocol has been registered with ClinicalTrials.gov: Trial Registration number: NCT05592028.
Feasibility of return to sports assessment 6 months after patellar instability surgery
Authors: Hysing-Dahl Trine , Magnussen L. H , Faleide A. G. H. , Inderhaug E. 
Published: August 2023

Abstract
Background
The evidence regarding the usefulness of assessment tools to support decisions of return-to-sport after surgery for patellar instability is scarce. The purpose of this study was therefore to explore the feasibility of functional tests assessing readiness for return-to-sport six months after patellar stabilizing surgery. However, there is little evidence on what a functional assessment should include to support these decisions following surgery for patellar instability. Therefore the purpose of this study was to explore the feasibility of functional tests assessing readiness for return-to-sport six months after patellar stabilizing surgery.

Methods
In this cross-sectional study a prospective cohort of 78 patients were subjected to a range of return-to-sport readiness tests at six months after surgery for patellar instability with an “a la carte” approach. Lower Quarter Y-Balance Test (YBT-LQ), single-legged hop tests and isokinetic strength tests were performed. In addition, self-reported function was measured with the Banff Patellofemoral Instability Instrument 2.0 (BPII) and Norwich Patellar Instability score (NPI). Return-to-sport clearance criteria were defined as: ≤4 cm YBT-LQ anterior reach difference between legs, leg-symmetry-index (LSI) ≥ 95% in the YBT-LQ composite score, mean sum score LSI ≥ 85% of all single-leg hop tests and LSI ≥ 90% in isokinetic quadriceps strength.

Results
Sixty-four patients (82%) were able to complete all functional tests, while only eleven (14%) patients were deemed ready for return-to-sport, passing all return-to-sport clearance criteria. Patients with bilateral problems demonstrated worse performance in the contralateral leg, which resulted in higher LSI scores compared to individuals with unilateral instability. A supplementary finding was that the extent of surgery (MPFL-R only versus combined surgery) did not predict and mainly did not affect self-reported function or functional performance at the follow-up.

Conclusion
The functional assessment used in the current study seems feasible to conduct at six months after patellar stabilizing surgery. However, current suggested clearance standards and the use of leg-symmetry-index seems inappropriate for patients with patellar instability. Therefore, further exploration of appropriate tests and return-to-sport clearance criteria is justified.

Trial registration
clinicaltrial.gov, NCT05119088. Registered 12.11.2021 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT05119088.
Human brain solute transport quantified by glymphatic MRI-informed biophysics during sleep and sleep deprivation
Authors: Vinje Vegard , Zapf Bastian , Ringstad Geir , Eide Per Kristian , Rognes Marie E. , Mardal Kent-Andre 
Published: August 2023

AbstractWhether you are reading, running or sleeping, your brain and its fluid environment continuously interacts to distribute nutrients and clear metabolic waste. Yet, the precise mechanisms for solute transport within the human brain have remained hard to quantify using imaging techniques alone. From multi-modal human brain MRI data sets in sleeping and sleep-deprived subjects, we identify and quantify CSF tracer transport parameters using forward and inverse subject-specific computational modelling. Our findings support the notion that extracellular diffusion alone is not sufficient as a brain-wide tracer transport mechanism. Instead, we show that human MRI observations align well with transport by either by an effective diffusion coefficent 3.5$$\times $$
×
that of extracellular diffusion in combination with local clearance rates corresponding to a tracer half-life of up to 5 h, or by extracellular diffusion augmented by advection with brain-wide average flow speeds on the order of 1–9 $$\mu $$
μ
m/min. Reduced advection fully explains reduced tracer clearance after sleep-deprivation, supporting the role of sleep and sleep deprivation on human brain clearance.
Is COVID-19 incriminated in new onset type 2 diabetes mellitus in Lebanese adults?
Authors: Jabbour Rose Mary , Hallit Souheil , Saliby Rita , Baydoun Abed El Karim , Nakhoul Nancy 
Published: August 2023

Abstract
Background
The effects of COVID-19 on the organism are still being investigated, especially after the transformation of this virus from a respiratory disease in its first appearance to a multi-organ disease that can affect nearly all systems and organs including the endocrinological system. The objective of the study was to find an association between COVID-19 infection and new onset type 2 diabetes in Lebanese adults.

Methods
A retrospective case–control study (2019–2022) included 200 subjects, 100 cases with new onset diabetes and 100 controls recruited from endocrinology clinics in rural and suburban located regions of Lebanon. Univariate and multivariate logistic regression were performed.

Results
Older age (aOR = 1.07; 95% CI 1.03–1.12), higher BMI (aOR = 1.32; 95% CI 1.17–1.48), having been infected with COVID-19 (aOR = 2.38; 95% CI 1.001–5.68) and having a family history of diabetes (aOR = 11.80; 95% CI 4.23–32.87) were significantly associated with higher odds of having new onset type 2 diabetes after adjusting for multiple risk factors.

Conclusion
In addition to the traditional risk factors for developing type 2 diabetes, a recent COVID-19 infection was associated with the new onset DM in our study. Subsequently screening for diabetes should be strongly recommended for patients post COVID-19 infection.
Sex differences in pre- and post-synaptic glutamate signaling in the nucleus accumbens core
Authors: Knouse Melissa C. , Deutschmann Andre U. , Nenov Miroslav N. , Wimmer Mathieu E. , Briand Lisa A. 
Published: August 2023

Abstract
Background
Glutamate signaling within the nucleus accumbens underlies motivated behavior and is involved in psychiatric disease. Although behavioral sex differences in these processes are well-established, the neural mechanisms driving these differences are largely unexplored. In these studies, we examine potential sex differences in synaptic plasticity and excitatory transmission within the nucleus accumbens core. Further understanding of baseline sex differences in reward circuitry will shed light on potential mechanisms driving behavioral differences in motivated behavior and psychiatric disease.

Methods
Behaviorally naïve adult male and female Long-Evans rats, C57Bl/6J mice, and constitutive PKMζ knockout mice were killed and tissue containing the nucleus accumbens core was collected for ex vivo slice electrophysiology experiments. Electrophysiology recordings examined baseline sex differences in synaptic plasticity and transmission within this region and the potential role of PKMζ in long-term depression.

Results
Within the nucleus accumbens core, both female mice and rats exhibit higher AMPA/NMDA ratios compared to male animals. Further, female mice have a larger readily releasable pool of glutamate and lower release probability compared to male mice. No significant sex differences were detected in spontaneous excitatory postsynaptic current amplitude or frequency. Finally, the threshold for induction of long-term depression was lower for male animals than females, an effect that appears to be mediated, in part, by PKMζ.

Conclusions
We conclude that there are baseline sex differences in synaptic plasticity and excitatory transmission in the nucleus accumbens core. Our data suggest there are sex differences at multiple levels in this region that should be considered in the development of pharmacotherapies to treat psychiatric illnesses such as depression and substance use disorder.
Cost-benefit analysis for evacuation decision-support: challenges and possible solutions for applications in areas of distributed volcanism
Authors: Wild Alec J. , Bebbington M. S. , Lindsay J. M. , Deligne N. I. 
Published: August 2023

AbstractDuring a volcanic crisis, evacuation is the most effective mitigation measure to preserve life. However, the decision to call an evacuation is typically complex and challenging, in part due to uncertainties related to the behaviour of the volcano. Cost-benefit analysis (CBA) can support decision-makers: this approach compares the cost of evacuating versus the expected loss from not evacuating, expressed as a ‘break-even’ probability of fatality. Here we combine CBA with a Bayesian Event Tree for Short-term Volcanic Hazard (BET_VHst) to create an evacuation decision-support tool to identify locations that are cost-beneficial to evacuate in the event of volcanic unrest within a distributed volcanic field. We test this approach with the monogenetic Auckland Volcanic Field (AVF), situated beneath the city of Auckland, New Zealand. We develop a BET_VHst for the AVF, extending a recently revised Bayesian Event Tree for Eruption Forecasting (BET_EF) to consider the eruptive style, phenomena produced, and the impact exceedance probability as a function of distance. The output of the BET_VHst is a probability of volcanic hazard impact at a given location. Furthermore, we propose amending the weight of the monitoring component within the BET_VHst framework to a transitional parameter, addressing limitations identified in a previous study. We examine how three possible transitional monitoring component weights affect the spatial vent likelihood and subsequent BET_VHst outputs, compared to the current default weight. For the CBA, we investigate four thresholds, based on two evacuation durations and two different estimates for the value of life that determine the cost of not evacuating. The combinations of CBA and BET_VHst are tested using a synthetic unrest dataset to define an evacuation area for each day. While suitable evacuation areas were identified, there are further considerations required before such an approach can be applied operationally to support crisis management.